MLANA and neoplasm: Interestingly, puupehenone (64) was also reported as useful in tumor immunotherapy, being attached to a modified antigenic peptide derived from Melan-A/MART-1 protein, frequently recognized by MHC class I-restricted CD8+ cytotoxic T-lymphocytes (CTL).